Fecal Microbiota Alterations Associated With Clinical and Endoscopic Response to Infliximab Therapy in Crohn’s Disease

Abstract

Background Gut microbiota dysbiosis is associated with the occurrence and development of Crohn disease (CD). Currently, infliximab (IFX) is used more and more to treat CD; however, gut microbiota alterations during IFX therapy are variable and sometimes even contradictory. We longitudinally identified microbial changes during IFX therapy associated with the clinical and endoscopic response to IFX treatment in CD. Methods Fecal-associated microbiota was analyzed using 16S sequencing in 49 patients with active CD who were prospectively recruited at baseline, week 6, and week 30, respectively. Moreover, a model trained on the gut microbiota alterations at week 6 was developed to investigate their potential to predict clinical and endoscopic responses to IFX therapy at weeks 14 and 30. Results Characteristics of fecal microbiota composition in patients with CD after IFX treatment displayed an increased diversity and richness, a significant gain in short-chain fatty acid -producing bacteria, and a loss of pathogenic bacteria. Furthermore, certain functional profiles of Kyoto Encyclopedia of Genes and Genomes pathways were predictably altered during the treatment period. Increased proportions of Lachnospiraceae and Blautia were associated with IFX efficacy; the combined increase of these taxa at week 6 showed 83.4% and 84.2% accuracy in predicting clinical response at weeks 14 and 30, respectively, with a predictive value of 89.1% in predicting endoscopic response at week 30. Conclusions We found that IFX diminished CD-related gut microbial dysbiosis by modifying microbiota composition and function. Specifically, increased Lachnospiraceae and Blautia at week 6 are associated with the clinical and endoscopic response to IFX, providing potentially predictive biomarkers for IFX treatment decision-making.

The Emulsifier Carboxymethylcellulose Induces More Aggressive Colitis in Humanized Mice with Inflammatory Bowel Disease Microbiota Than Polysorbate-80

“…These results suggest that P80 may stimulate a more protective microbiota composition than does CMC in our model. The concept of P80 inducing more protective microbiota is supported by higher bacterial diversity and richness in P80-treated mice compared with CMC treatment [38]. Similarly, we showed higher Shannon-α diversity of the microbiome in P80 vs. CMCtreated mice, and a trend toward higher diversity in P80-treated mice relative to water controls.…”

The Gut Microbiota in Inflammatory Bowel Disease

“…Zhuang et al showed that the diversity and richness of the fecal microbiota in CD patients increased significantly after infliximab treatment, the number of bacteria-producing SCFAs increased, and the number of pathogenic bacteria decreased. Although anti-TNF therapy has changed the drug regimen for treatment of IBD, up to 30% of patients achieved no clinical benefit after the induction period, and up to 50% of patients have to withdraw from treatment (Zhuang et al, 2020).…”

Persistent Response and Prolonged Survival Following Pembrolizumab Discontinuation Due to Long-Lasting Autoimmune Colitis in Advanced NSCLC: A Case Report

“…Once clinical improvement to grade 1 or less is achieved, steroids should be progressively reduced, and anti-PD-1/L1 inhibitors can usually be resumed when symptoms have resolved or prednisone is tapered to daily doses of 10 mg or less. The risk of recurrent gastrointestinal irAEs is reported as high as 19-36% (17). Cases of persistent inflammation up to 6-18 months from initial diagnosis ( 18) are described, as in our clinical case.…”